Cost-effectiveness of Interventions for the Prevention and Control of COVID-19: Systematic Review of 85 Modelling Studies

Overview

Journal J Glob Health

Specialties Health Services
Public Health

Date 2022 Jun 17

PMID 35712857

Authors

Lihui Zhou

Wenxin Yan

Shu Li

Hongxi Yang

Xinyu Zhang

Wenli Lu

Jue Liu

Yaogang Wang

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to quantitatively summarise the health economic evaluation evidence of prevention and control programs addressing COVID-19 globally.

Methods: We did a systematic review and meta-analysis to assess the economic and health benefit of interventions for COVID-19. We searched PubMed, Embase, Web of Science, and Cochrane Library of economic evaluation from December 31, 2019, to March 22, 2022, to identify relevant literature. Meta-analyses were done using random-effects models to estimate pooled incremental net benefit (INB). Heterogeneity was assessed using I statistics and publication bias was assessed by Egger's test. This study is registered with PROSPERO, CRD42021267475.

Results: Of 16 860 studies identified, 85 articles were included in the systematic review, and 25 articles (10 studies about non-pharmacological interventions (NPIs), five studies about vaccinations and 10 studies about treatments) were included in the meta-analysis. The pooled INB of NPIs, vaccinations, and treatments were $1378.10 (95% CI = $1079.62, $1676.59), $254.80 (95% CI = $169.84, $339.77) and $4115.11 (95% CI = $1631.09, $6599.14), respectively. Sensitivity analyses showed similar findings.

Conclusions: NPIs, vaccinations, and treatments are all cost-effective in combating the COVID-19 pandemic. However, evidence was mostly from high-income and middle-income countries. Further studies from lower-income countries are needed.

Citing Articles

Health and Economic Impact of COVID-19 Surveillance Testing in Seattle Homeless Shelters: A Cost-Effectiveness Analysis.

Cox S, Chow E, Rolfes M, Mosites E, Sharma M, Chu H AJPM Focus. 2025; 4(2):100307.

PMID: 40061153 PMC: 11889550. DOI: 10.1016/j.focus.2024.100307.

Cost-effectiveness of preventive COVID-19 interventions: a systematic review and network meta-analysis of comparative economic evaluation studies based on real-world data.

Tang X, Sun S, Memedi M, Hiyoshi A, Montgomery S, Cao Y J Glob Health. 2025; 15:04017.

PMID: 39977668 PMC: 11842005. DOI: 10.7189/jogh.15.04017.

Health-economic evaluation of the outpatient, inpatient, and public health sector in Germany: Insights from the first three COVID-19 waves.

Gandjour A PLoS One. 2025; 20(2):e0314164.

PMID: 39919135 PMC: 11805348. DOI: 10.1371/journal.pone.0314164.

From node to network: weaving a global perspective on efficacy and costs of non-pharmaceutical interventions.

Xu C, Kumar S, Yang M, Ghildayal N, Chandra C Sci Rep. 2025; 15(1):2844.

PMID: 39843823 PMC: 11754695. DOI: 10.1038/s41598-025-87566-8.

Global infectious disease early warning models: An updated review and lessons from the COVID-19 pandemic.

Hu W, Sun H, Wei Y, Hao Y Infect Dis Model. 2025; 10(2):410-422.

PMID: 39816751 PMC: 11731462. DOI: 10.1016/j.idm.2024.12.001.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Oksuz E, Malhan S, Gonen M, Kutlubay Z, Keskindemirci Y, Jarrett J . Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey. Adv Ther. 2021; 38(9):4935-4948. PMC: 8355577. DOI: 10.1007/s12325-021-01874-9. View

Sathian B, Asim M, Banerjee I, Roy B, Pizarro A, Mancha M . Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. Nepal J Epidemiol. 2021; 11(1):959-982. PMC: 8033643. DOI: 10.3126/nje.v11i1.36163. View

Du Z, Wang L, Bai Y, Wang X, Pandey A, Fitzpatrick M . Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. Lancet Reg Health Am. 2022; 8:100182. PMC: 8759769. DOI: 10.1016/j.lana.2021.100182. View

Pang Q, He W, Li J, Huang L . Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review. World J Clin Cases. 2020; 8(23):6181-6189. PMC: 7723689. DOI: 10.12998/wjcc.v8.i23.6181. View

Kazungu J, Munge K, Werner K, Risko N, Vecino-Ortiz A, Were V . Examining the cost-effectiveness of personal protective equipment for formal healthcare workers in Kenya during the COVID-19 pandemic. BMC Health Serv Res. 2021; 21(1):992. PMC: 8451734. DOI: 10.1186/s12913-021-07015-w. View

Rafia R, Martyn-St James M, Harnan S, Metry A, Hamilton J, Wailoo A . A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales. Value Health. 2022; 25(5):761-769. PMC: 8858417. DOI: 10.1016/j.jval.2021.12.015. View

Reddy K, Fitzmaurice K, Scott J, Harling G, Lessells R, Panella C . Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. Nat Commun. 2021; 12(1):6238. PMC: 8556310. DOI: 10.1038/s41467-021-26557-5. View

Asamoah J, Owusu M, Jin Z, Oduro F, Abidemi A, Gyasi E . Global stability and cost-effectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana. Chaos Solitons Fractals. 2020; 140:110103. PMC: 7351453. DOI: 10.1016/j.chaos.2020.110103. View

10.

Suso-Marti L, La Touche R, Herranz-Gomez A, Angulo-Diaz-Parreno S, Paris-Alemany A, Cuenca-Martinez F . Effectiveness of Telerehabilitation in Physical Therapist Practice: An Umbrella and Mapping Review With Meta-Meta-Analysis. Phys Ther. 2021; 101(5). PMC: 7928612. DOI: 10.1093/ptj/pzab075. View

11.

Bartsch S, Ferguson M, McKinnell J, OShea K, Wedlock P, Siegmund S . The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. Health Aff (Millwood). 2020; 39(6):927-935. PMC: 11027994. DOI: 10.1377/hlthaff.2020.00426. View

12.

Vaezi A, Meysamie A . COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. Vaccines (Basel). 2022; 10(1). PMC: 8777749. DOI: 10.3390/vaccines10010037. View

13.

Bastiampillai T, Allison S, Looi J, Licinio J, Wong M, Perry S . The COVID-19 pandemic and epidemiologic insights from recession-related suicide mortality. Mol Psychiatry. 2020; 25(12):3445-3447. PMC: 7462110. DOI: 10.1038/s41380-020-00875-4. View

14.

Risko N, Werner K, Offorjebe O, Vecino-Ortiz A, Wallis L, Razzak J . Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic. PLoS One. 2020; 15(10):e0240503. PMC: 7546502. DOI: 10.1371/journal.pone.0240503. View

15.

Carta A, Conversano C . Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res. 2021; 21(1):986. PMC: 8449700. DOI: 10.1186/s12913-021-06998-w. View

16.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

17.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

18.

Tsao Y, Thanh V, Chang Y, Wei H . COVID-19: Government subsidy models for sustainable energy supply with disruption risks. Renew Sustain Energy Rev. 2021; 150:111425. PMC: 8441177. DOI: 10.1016/j.rser.2021.111425. View

19.

Du Z, Pandey A, Bai Y, Fitzpatrick M, Chinazzi M, Pastore Y Piontti A . Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health. 2021; 6(3):e184-e191. PMC: 7862022. DOI: 10.1016/S2468-2667(21)00002-5. View

20.

Sinha P, Linas B . Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality. Clin Infect Dis. 2021; 73(11):2116-2118. PMC: 8135952. DOI: 10.1093/cid/ciab409. View